Vertaling van "productivity gains have been mostly " (Nederlands → Frans) :

Gross margin improvements from productivity gains have been mostly reinvested to support the Prevacid24HR launch in the US and sales force expansion across all businesses.
Les gains de productivité ayant permis d’améliorer la marge brute ont été en majorité réinvestis dans le lancement de Prevacid24HR aux Etats-Unis et dans l’expansion de la force de vente dans toutes les activités.

In Europe, where pricing pressures have been most intense, overall growth was 8 %, with volume gains of 12 percentage points demonstrating the quality of the new product portfolio.
En Europe, où la pression sur les prix a été la plus forte, la croissance globale s’est inscrite à 8%, avec des gains en volume de 12 points ce qui démontre la qualité des nouveaux produits.

Gross profit margin improvements, productivity gains, and income from an OTC US non-core brand divestment have been the growth drivers, partially offset by higher investments in Marketing & Sales to support new product launches and sales force expansions.
Des améliorations de la marge brute, des gains de productivité et le produit de la cession d’une marque non stratégique d’OTC aux Etats-Unis ont été le moteur de la croissance, qui a été en partie freinée par une hausse des investissements dans Marketing et vente pour soutenir le lancement de nouveaux produits et l’extension des forces de vente.

Accordingly, what follows is not meant as an exhaustive inventory of all the initiatives that have already been taken at all the levels of authority, but as a grouping together of various examples of initiatives taken in this field, based on the most important courses of action.
La présentation qui suit ne vise donc pas à dresser un inventaire exhaustif de toutes les initiatives déjà prises à tous les niveaux de pouvoir mais bien de regrouper à partir des axes d’actions principaux divers exemples d’initiatives prises dans le domaine.

As mentioned above, quite a number of considerations and advisory reports have been issued about “Red Bull”, which was, historically, the first of these beverages and is still the most famous.
Comme indiqué ci-avant, bon nombre de considérations et avis rendus ont porté sur « Red Bull », historiquement la première mais aussi encore actuellement la plus connue de ces boissons.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Newly launched products, such as enoxaparin, losartan, and tacrolimus, have been key in driving year-to-date growth.
Depuis le début de l’année, les produits lancés nouvellement, comme énoxaparine, losaratan et tacrolimus, ont tiré la croissance vers le haut.

At our Tongi plant in Bangladesh, streamlined production lines have improved energy efficiency; the use of water pumps, chillers and cooling tower fans has been minimized.
Dans notre usine de Tongi, au Bangladesh, la rationalisation des lignes de production a permis d’améliorer le bilan énergétique global : utilisation plus restreinte des pompes à eau, des ventilateurs et des tours de refroidissement.

De termen en voorwaarden opgenomen in het register op de website van de Europese Commissie vermelden “health claims should only be made for the nutrient, substance, food or food category for which they have been authorised, and not for the food product that contains them”.
Les termes et conditions repris sur le registre du site de la Commission européenne mentionnent que “health claims should only be made for the nutrient, substance, food or food category for which they have been authorised, and not for the food product that contains them”.

Nevertheless, in view of the fact that this type of drink is already allowed in several European countries and taking into account the European regulations concerning this type of product, in the end, the competent French authorities have been obliged to give their approval (Decree of the European Court of Justice, Press release No. 12/04, 2004) for this beverage, which was marketed on 15 July 2008.
Néanmoins, considérant que ce type de boisson est déjà autorisé dans plusieurs pays d’européens et compte tenu de la réglementation européenne sur ce type de produit, les autorités compétentes françaises ont finalement dû l’autoriser (Arrêt de la Cour de Justice européenne, Communiqué de presse n° 12/04, 2004). Sa commercialisation a effectivement débuté en date du 15 juillet 2008.